This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Diversified Operations Industry Outlook Bleak on Coronavirus Woes
by Payal Jalan
The pandemic's adverse impacts on multiple end markets, especially commercial aerospace, general industrial and others, hurt the diversified operations industry's prospects. However, pandemic-induced demand for many products might aid.
Danaher's Stock Offering Proceeds to Fund Corporate Needs
by Zacks Equity Research
Danaher (DHR) completes the offering of common and convertible preferred shares. It intends on using the funds raised to pay for its corporate needs.
Danaher (DHR) Beats Q1 Earnings Estimates, Provides Bleak View
by Zacks Equity Research
Danaher's (DHR) Q1 results reflect healthy growth in organic sales and the impacts of forex woes. Core sales in Q2 are expected to reflect the pandemic woes and gains from Cytiva.
Danaher (DHR) Q1 Earnings Top Estimates
by Zacks Equity Research
Danaher (DHR) delivered earnings and revenue surprises of 5.00% and -0.16%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Is a Surprise Coming for Danaher (DHR) This Earnings Season?
by Zacks Equity Research
Danaher (DHR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Danaher (DHR) to Report Q1 Earnings: Is a Beat in Store?
by Zacks Equity Research
Danaher's (DHR) Q1 results are expected to reflect healthy segmental growth. However, adverse impacts of the coronavirus outbreak on demand are anticipated to have ailed.
Timing the Market, Is it Possible? - May 04, 2020
by Zacks Equity Research
In the long-run, does consistent market timing really matter to be a successful investor?
Danaher (DHR) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Danaher (DHR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Can Danaher (DHR) Keep the Earnings Surprise Streak Alive?
by Zacks Equity Research
Danaher (DHR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
General Electric (GE) Q1 Earnings Lag Estimates, View Gloomy
by Zacks Equity Research
General Electric's (GE) first-quarter 2020 earnings reflect the adverse impacts of the coronavirus outbreak. Persistence of the headwinds is likely to impact second-quarter results as well.
The Coronavirus Impact on Corporate Earnings
by Sheraz Mian
We discuss today the Covid-19 impact on corporate earnings, in addition to featuring new research reports on AP (SAP), NIKE (NKE) and others.
Healthy Business to Aid Danaher in Q1 Despite Coronavirus Woes
by Zacks Equity Research
Danaher's (DHR) healthy businesses are likely to aid, driven by segmental performances in the first quarter of 2020. However, concerns related to the coronavirus outbreak persist.
When Does Market Timing Actually Work? - April 14, 2020
by Zacks Equity Research
In the long-run, does consistent market timing really matter to be a successful investor?
General Electric Take Multiple Debt Restructuring Actions
by Zacks Equity Research
General Electric (GE) commences multiple actions to strengthen its financial positions. Proceeds from the BioPharma divestment and new debt offerings have been used for reducing leverage.
Danaher Gives Update on Q1 Results, Withdraws 2020 Guidance
by Zacks Equity Research
Danaher (DHR) provides an update on first-quarter 2020 results and withdraws its earlier announced guidance for 2020 on the impacts of the coronavirus outbreak.
General Electric Withdraws 2020 View on Coronavirus Concerns
by Zacks Equity Research
General Electric (GE) suspends 2020 projections on uncertainties related to the coronavirus outbreak. Also, earnings in the first quarter are expected to be weaker than previously expected.
Analysts Estimate Danaher (DHR) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Danaher (DHR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Danaher (DHR) Prices Senior Notes Offering Worth Euro 750M
by Zacks Equity Research
Danaher (DHR) prices euro 750 million worth of senior notes offerings. The net proceeds will be used for satisfying generate corporate purposes, including repaying debts.
Danaher Closes Buyout of General Electric's BioPharma Business
by Zacks Equity Research
Danaher (DHR) completes the acquisition of General Electric's BioPharma business. The buyout will likely strengthen the company's biologics workflow solutions business.
General Electric Closes Divestment of BioPharma to Danaher
by Zacks Equity Research
General Electric (GE) completes the divestment of its BioPharma business to Danaher. The net proceeds received from the transaction will be used by General Electric to lower its debt burden.
Top Stock Reports for Stryker, Shopify & Activision Blizzard
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Stryker (SYK), Shopify (SHOP) and Activision Blizzard (ATVI).
Danaher (DHR) Prices Euro 1.75B Worth Senior Notes Offering
by Zacks Equity Research
Danaher (DHR) prices euro 1.75 billion worth of senior notes offerings. The net proceeds will be used for satisfying generate corporate purposes, including repaying debts.
Conglomerates Accelerate Efforts to Fight Coronavirus Menace
by Avisekh Bhattacharjee
Several industrial conglomerates including General Electric (GE), Honeywell (HON), Danaher (DHR) and 3M (MMM) are increasing steps to mitigate the effects of the coronavirus menace.
General Electric Announces Coronavirus' Impacts on Its Business
by Zacks Equity Research
General Electric's (GE) aviation segment seeks to lower the U.S. workforce by 10% on coronavirus concerns. The company announces various other measures to deal with the impact of the outbreak.
The Zacks Analyst Blog Highlights: Danaher, Quidel, Aytu BioScience, QIAGEN and Co-Diagnostics
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Danaher, Quidel, Aytu BioScience, QIAGEN and Co-Diagnostics